{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:07:05Z","timestamp":1788264425864,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.lfs.2021.119392","type":"journal-article","created":{"date-parts":[[2021,3,24]],"date-time":"2021-03-24T07:26:34Z","timestamp":1616570794000},"page":"119392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy"],"prefix":"10.1016","volume":"276","author":[{"given":"Lulu","family":"Cui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongtao","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ni","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lfs.2021.119392_bb0005","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"6","key":"10.1016\/j.lfs.2021.119392_bb0010","doi-asserted-by":"crossref","DOI":"10.1007\/s11864-018-0547-8","article-title":"Anthracycline use for early stage breast cancer in the modern era: a review","volume":"19","author":"Jasra","year":"2018","journal-title":"Curr. Treat. Options in Oncol."},{"key":"10.1016\/j.lfs.2021.119392_bb0015","article-title":"Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer","volume":"2","author":"Zaheed","year":"2019","journal-title":"Cochrane Database Systematic Rev."},{"key":"10.1016\/j.lfs.2021.119392_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.breast.2019.06.003","article-title":"Anthracycline could be essential for triple-negative breast cancer: a randomised phase II study by the Kanagawa Breast Oncology Group (KBOG) 1101","volume":"47","author":"Narui","year":"2019","journal-title":"Breast (Edinburgh, Scotland)"},{"issue":"24","key":"10.1016\/j.lfs.2021.119392_bb0025","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1093\/jnci\/92.24.1991","article-title":"HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15","volume":"92","author":"Paik","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.lfs.2021.119392_bb0030","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1023\/B:BREA.0000032983.87966.4e","article-title":"Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23","volume":"86","author":"Land","year":"2004","journal-title":"Breast Cancer Res. Treat."},{"issue":"1","key":"10.1016\/j.lfs.2021.119392_bb0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djm252","article-title":"HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials","volume":"100","author":"Gennari","year":"2008","journal-title":"J. Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.lfs.2021.119392_bb0040","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.prp.2014.06.017","article-title":"Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer","volume":"210","author":"Almeida","year":"2014","journal-title":"Pathol. Res. Pract."},{"issue":"9472","key":"10.1016\/j.lfs.2021.119392_bb0045","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","year":"2005","journal-title":"Lancet (London, England)"},{"issue":"1","key":"10.1016\/j.lfs.2021.119392_bb0050","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-018-4365-y","article-title":"Retrospective analysis of the impact of anthracycline dose reduction and chemotherapy delays on the outcomes of early breast cancer molecular subtypes","volume":"18","author":"Liutkauskiene","year":"2018","journal-title":"BMC Cancer"},{"issue":"2","key":"10.1016\/j.lfs.2021.119392_bb0055","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3892\/ol.2020.12361","article-title":"Cardiotoxicity of anthracycline-free targeted oncological therapies in HER2-positive breast cancer","volume":"21","author":"Guan","year":"2021","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.lfs.2021.119392_bb0060","first-page":"1","article-title":"Anthracycline-induced cardiotoxicity: the role of endothelial dysfunction","author":"Grakova","year":"2021","journal-title":"Cardiology"},{"issue":"7","key":"10.1016\/j.lfs.2021.119392_bb0065","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00520-011-1241-6","article-title":"Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy","volume":"20","author":"Chan","year":"2012","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.lfs.2021.119392_bb0070","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000449226","article-title":"Incidence and predictors of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy in Korea","volume":"91","author":"Kim","year":"2016","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.lfs.2021.119392_bb0075","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/s41598-020-80415-w","article-title":"Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin","volume":"11","author":"Liu","year":"2021","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.lfs.2021.119392_bb0080","first-page":"617","article-title":"Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)","volume":"42","year":"2020","journal-title":"Zhonghua zhong liu za zhi [Chinese J. Oncol.]"},{"issue":"2","key":"10.1016\/j.lfs.2021.119392_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","article-title":"Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer \u2014 a retrospective review of Chinese patients and comparison with an historic Western series","volume":"62","author":"Ma","year":"2002","journal-title":"Radiother. Oncol."},{"issue":"33","key":"10.1016\/j.lfs.2021.119392_bb0090","first-page":"1","article-title":"The clinical effectiveness and cost-effectiveness of genotyping for CYP2D6 for the management of women with breast cancer treated with tamoxifen: a systematic review","volume":"15","author":"Fleeman","year":"2011","journal-title":"Health Technol. Assess. (Winchester, England)"},{"issue":"24","key":"10.1016\/j.lfs.2021.119392_bb0095","doi-asserted-by":"crossref","first-page":"7988","DOI":"10.1158\/1078-0432.CCR-08-1211","article-title":"Advances in breast cancer: pathways to personalized medicine","volume":"14","author":"Olopade","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.lfs.2021.119392_bb0100","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00280-011-1625-9","article-title":"The effects of CYP3A4, CYP3A5, ABCB1, ABCC2, ABCG2 and SLCO1B3 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of docetaxel in nasopharyngeal carcinoma patients","volume":"67","author":"Chew","year":"2011","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"6","key":"10.1016\/j.lfs.2021.119392_bb0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/14622416.8.6.567","article-title":"Novel SLC22A16 polymorphisms and influence on doxorubicin pharmacokinetics in Asian breast cancer patients","volume":"8","author":"Lal","year":"2007","journal-title":"Pharmacogenomics"},{"issue":"3","key":"10.1016\/j.lfs.2021.119392_bb0110","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.bbrc.2005.05.174","article-title":"Characterization of the organic cation transporter SLC22A16: a doxorubicin importer","volume":"333","author":"Okabe","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.lfs.2021.119392_bb0115","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.ddtec.2014.03.004","article-title":"Transporter taxonomy - a comparison of different transport protein classification schemes","volume":"12","author":"Viereck","year":"2014","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.lfs.2021.119392_bb0120","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-12-381","article-title":"Role of aldo-keto reductases and other doxorubicin pharmacokinetic genes in doxorubicin resistance, DNA binding, and subcellular localization","volume":"12","author":"Heibein","year":"2012","journal-title":"BMC Cancer"},{"issue":"10","key":"10.1016\/j.lfs.2021.119392_bb0125","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1111\/j.1349-7006.2008.00903.x","article-title":"CBR1 and CBR3 pharmacogenetics and their influence on doxorubicin disposition in Asian breast cancer patients","volume":"99","author":"Lal","year":"2008","journal-title":"Cancer Sci."},{"issue":"5","key":"10.1016\/j.lfs.2021.119392_bb0130","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1124\/dmd.107.018895","article-title":"Two allelic variants of aldo-keto reductase 1A1 exhibit reduced in vitro metabolism of daunorubicin","volume":"36","author":"Bains","year":"2008","journal-title":"Drug Metab. Disposition: Biol. Fate Chem."},{"issue":"8","key":"10.1016\/j.lfs.2021.119392_bb0135","first-page":"611","article-title":"C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance","volume":"1","author":"Imai","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"3","key":"10.1016\/j.lfs.2021.119392_bb0140","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin. Radiat. Oncol."},{"issue":"5","key":"10.1016\/j.lfs.2021.119392_bb0145","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1186\/bcr618","article-title":"First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study","volume":"5","author":"Rivera","year":"2003","journal-title":"Breast Cancer Res."},{"issue":"12","key":"10.1016\/j.lfs.2021.119392_bb0150","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/sj.bjc.6604094","article-title":"Does chemotherapy-induced neutropaenia result in a postponement of adjuvant or neoadjuvant regimens in breast cancer patients? Results of a retrospective analysis","volume":"97","author":"Debled","year":"2007","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.lfs.2021.119392_bb0155","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","article-title":"Risk factors for chemotherapy-induced neutropenia occurrence in breast cancer patients: data from the INC-EU Prospective Observational European Neutropenia Study","volume":"19","author":"Schwenkglenks","year":"2011","journal-title":"Support Care Cancer"},{"issue":"23","key":"10.1016\/j.lfs.2021.119392_bb0160","doi-asserted-by":"crossref","first-page":"5555","DOI":"10.1002\/cncr.25332","article-title":"Risk of mortality in patients with cancer who experience febrile neutropenia","volume":"116","author":"Lyman","year":"2010","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.lfs.2021.119392_bb0165","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/03602532.2016.1226896","article-title":"Pharmacogenetics of irinotecan, doxorubicin and docetaxel transporters in Asian and Caucasian cancer patients: a comparative review","volume":"48","author":"Chen","year":"2016","journal-title":"Drug Metab. Rev."},{"issue":"2","key":"10.1016\/j.lfs.2021.119392_bb0170","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1517\/14622416.6.2.115","article-title":"Mechanisms of resistance to anticancer drugs: the role of the polymorphic ABC transporters ABCB1 and ABCG2","volume":"6","author":"Lepper","year":"2005","journal-title":"Pharmacogenomics"},{"issue":"5","key":"10.1016\/j.lfs.2021.119392_bb0175","first-page":"6291","article-title":"Association between CBR1 polymorphisms and NSCLC in the Chinese population","volume":"14","author":"Guo","year":"2017","journal-title":"Oncol. Lett."},{"issue":"6","key":"10.1016\/j.lfs.2021.119392_bb0180","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1159\/000362437","article-title":"Retrospective analysis of severe neutropenia in patients receiving concomitant administration of docetaxel and clarithromycin","volume":"59","author":"Tsuji","year":"2013","journal-title":"Chemotherapy"},{"issue":"24","key":"10.1016\/j.lfs.2021.119392_bb0185","doi-asserted-by":"crossref","first-page":"4524","DOI":"10.1200\/JCO.2003.05.002","article-title":"Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices","volume":"21","author":"Lyman","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.lfs.2021.119392_bb0190","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0167-8140(02)00003-8","article-title":"Acute toxicity of adjuvant doxorubicin and cyclophosphamide for early breast cancer \u2014 a retrospective review of Chinese patients and comparison with an historic Western series","volume":"62","author":"Ma","year":"2002","journal-title":"Radiother. Oncol."},{"issue":"7","key":"10.1016\/j.lfs.2021.119392_bb0195","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdr493","article-title":"Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer","volume":"23","author":"Jenkins","year":"2012","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.lfs.2021.119392_bb0200","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","article-title":"2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours","volume":"47","author":"Aapro","year":"2011","journal-title":"Eur. J. Cancer (Oxford, England: 1990)"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521003775?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320521003775?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T21:26:43Z","timestamp":1698096403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320521003775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":40,"alternative-id":["S0024320521003775"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119392","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between the genetic polymorphisms of the pharmacokinetics of anthracycline drug and myelosuppression in a patient with breast cancer with anthracycline-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"Life Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lfs.2021.119392","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"119392"}}